LimeLight of The week is

InMed Pharmaceuticals Inc.
(NASDAQ: INM)

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the development, manufacture and commercialization of rare cannabinoids for pharmaceutical and consumer health and wellness applications. InMed is a clinical stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab.

In October 2021, InMed announced its acquisition of BayMedica Inc., a private U.S. firm specializing in the manufacture and commercialization of rare cannabinoids for the health and wellness sector. BayMedica, now operating as a subsidiary of InMed, is a revenue-stage biotechnology firm leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa (EB), a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. A Phase 2 clinical trial in EB is currently underway, marking the first time that a CBN-based formulation has advanced to a Phase 2 clinical trial. The study is taking place at 13 sites across eight countries in Europe, with patient screening and treatment currently ongoing.

InMed is also developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Investment Considerations

• InMed has a world class leadership team with a successful track record of drug development and commercialization.
• InMed has a solid and expanding intellectual property portfolio with multiple patents filed.
• The company recently acquired rare cannabinoids manufacturer BayMedica.
• InMed retains all commercial rights to its IntegraSyn manufacturing system.
• InMed has commenced a Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa.
• The consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029.

Recent Coverage

InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Expansion of Rare Cannabinoid Portfolio

April 21, 2022 8:30 AM

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is launching business-to-business sales of its rare cannabinoid cannabidivarin (“CBDV”). Through subsidiary BayMedica LLC, InMed will offer its product to wholesalers, suppliers and end-product manufacturers in the health and wellness sector. In addition, the company released a white paper focused on research into the therapeutic potential of CBDV. According to the announcement, CBDV is a nonintoxicating rare cannabinoid that is similar to CBD but offers important differences in activity. One of the most-studied rare cannabinoids, CBDV is currently the focus of several different clinical trials evaluating its use in the treatment of autism, Prader-Willi Syndrome and attention deficit hyperactivity disorder. “Ensuring a reliable, large volume source of highly pure, bioidentical CBDV is an important step forward in the health and wellness sector,” said BayMedica SVP and general manager Shane Johnson in the press release. “CBDV has been researched for its therapeutic potential in several disease areas such as autism spectrum disorder. Whether you are a researcher or product developer at a multinational consumer package goods company, the ability to access highly pure and consistent active ingredients, free from contaminants typically found in plant-sourced cannabinoids such as pesticides, heavy metals, or potentially even THC, is a fundamental requirement. BayMedica’s cannabinoid manufacturing technologies provides exactly that value and we are excited to continue to introduce to the market additional rare cannabinoids that have previously not been abundantly accessible, including adding THCV to our portfolio in the immediate future.”

To view the full source article, visit: THIS LINK

Receive SMS Text Alerts from CannabisNewsWire

Text "Cannabis" to 844-397-5787

(US Mobile Phones Only)

Featured Event

Lift&Co. Expo Toronto 2022
5/12 - 5/15, 2022 - Toronto

Canada's #1 Cannabis Conference & Trade Show returns this May, with so much new in store for 2022!

Lift Cannabis Business Conference

Lift Cannabis Business Conference (LCBC) is the premiere gathering of Canada's top business leaders, subject matter experts, innovators, and regulators, across the cannabis industry. Each speaker, presentation, and panel offers leading-edge education on the most important issues facing Canada's cannabis business sector today. This exclusive, full-day conference takes place May 12, 2022, prior to Lift&Co. Expo Industry Days and Consumer Day.

For more information, please visit https://liftexpo.ca/

LIFT&CO. EXPO PARTNERS

Join our 200+ partners from across Canada and around the world!

As the largest industry & consumer cannabis event in Canada, Lift&Co. Expo is a can't miss opportunity to connect & move forward with the industry.  As a partner at Lift&Co. Expo, you'll have an unmatched opportunity to:

• Connect with 1000's of Attendees & Exhibitors
• Build Brand Awareness
• Explore Global Expansion Opportunities
• Network & Engage with Unique Audiences

Upcoming Events

• NECANN’s New York Cannabis Convention — New York City — 5/14 - 5/15
• Alternative Products Expo, Colombia — Medellin, Colombia — 5/21 - 5/22
• BizCann Expo, Medellin, Columbia — Medellin, Colombia — 5/21 - 5/22
• O’Cannabiz Toronto — Toronto — 6/1 - 6/3

About CannabisNewsWire (CNW)

CannabisNewsWire (CNW) is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. Leveraging a professional team of journalists and writers, CNW introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network of over 5,000 key distribution outlets. Cutting through information overload, CNW's innovative and proprietary systems clearly and succinctly deliver its clients much needed visibility, recognition and brand awareness. CNW is where news, content and information converge.